Castleark Management LLC Supernus Pharmaceuticals, Inc. Transaction History

Castleark Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $1.83 Million - $2.2 Million	52,440 Added 89.73%	110,880 $4.02 Million
Q4 2022 Feb 09, 2023	BUY	$31.09 - $37.88 $32,644 - $39,774	1,050 Added 1.83%	58,440 $2.08 Million
Q3 2022 Nov 15, 2022	SELL	$28.79 - $35.41 $420,334 - $516,985	-14,600 Reduced 20.28%	57,390 $1.94 Million
Q2 2022 Aug 16, 2022	BUY	$25.33 - $34.25 $760,153 - $1.03 Million	30,010 Added 71.49%	71,990 $2.08 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $1.2 Million - $1.38 Million	41,980 New	41,980 $1.36 Million
Q1 2019 May 14, 2019	SELL	$32.77 - $41.99 $140,255 - $179,717	-4,280 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$42.7 - $56.55 $12.7 Million - $16.8 Million	-297,565 Reduced 98.58%	4,280 $215,000
Q2 2018 Aug 15, 2018	BUY	$44.1 - $59.85 $13.3 Million - $18.1 Million	301,845 New	301,845 $18.1 Million
Q4 2017 Feb 15, 2018	SELL	$36.4 - $42.6 $11.5 Million - $13.5 Million	-316,940 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$36.75 - $49.65 $11.6 Million - $15.7 Million	316,940	316,940 $12.7 Million

302

60.6M

25.2K

2.6K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.